Tiger Brokers

BUZZ-Capricor climbs as FDA clears path for resubmission of cell therapy application

Reuters
Sep 25, 2025
BUZZ-Capricor climbs as FDA clears path for resubmission of cell therapy application

** Shares of therapy developer Capricor Therapeutics CAPR.O rise 1.6% to $6.29 premarket

** Co says it has completed a key clinical trial for its muscle disorder therapy and expects to share results by Q4

** Co says the U.S. FDA has agreed that data from the trial could be used to support its marketing application for the cell therapy, Deramiocel

** Deramiocel is being developed to treat Duchenne muscular dystrophy, a rare and progressive genetic disorder that causes muscle degeneration and weakness

** In July, the agency declined to approve Deramiocel and requested more data

** Capricor says it has addressed all manufacturing-related issues

** As of last close, stock down 55% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10